@applefoot I have taken your advice and read the NOX piece on NOX66:
.....NOX66 has been designed to stop idronoxil being subject to Phase 2 metabolism. The drug is formulated in a fatty mixture designed to prevent the transferase enzymes in the lining of the gut and in the liver from attaching a sugar. The result being that the idronoxil theoretically reaches the cancer cell in a form that is highly active, with its attached fatty construct meant to actually assist the drug in accessing the cancer cell....
"fatty mixture" which would be a construct? and fat is a lipid from my understanding - this then made me ponder over Kazia's Trilexium with its "proprietary lipid construct" over which I believe Kazia has a granted patent?.
"The liver" now this was mentioned in a CEO/Chairman email to @Stayso 54 which was posted on HC on the 16th of April 2014:
...We are in the business of drugs, not drug delivery systems. The systems we are looking at are either on the market (eg. Abraxane, Doxil, Captisol) or in clinical studies, so we are not re-inventing the wheel..
...Our reason for using a construct is unusual. We want to keep the drug away from the liver. This is a hard-learnt lesson from OVATURE and other clinical experiences. By being in a construct, the drug avoids being taken up by the liver, avoids being conjugated (thereby rendering it inactive), and delivers the drug directly to the tumor cells. The well-established principle is that tumor cells are hungrier than normal cells and grab any protein or fat that comes their way. The construct serves as a Trojan Horse, carrying the drug into the cancer cell...
Actually fat gets a second mention in this email from the then Novogen CEO/Chairman.
Idronoxil I believe is of no consequence to Kazia shareholders because they never thought they owned it in the first place - why would they have when some are dual KZA/MEIP shareholders...?
How do you understand these events? Thoughts?
KZA Price at posting:
34.0¢ Sentiment: Buy Disclosure: Held
